Probiotics for preventing relapse or recurrence in Crohn's disease involving the ileum: Are there reasons for failure?

Journal of Crohn's and Colitis

Volumn 1, Issue 1, 2007, Pages 47-52

  Cabré, Eduard ^a   A Gassull, Miquel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Crohn's disease; Defensins; Dysbiosis; Innate immunity; Probiotics; Ulcerative colitis

Indexed keywords

DEFENSIN; MESALAZINE; PROBIOTIC AGENT; RIFAXIMIN;

ARTICLE; BIFIDOBACTERIACEAE; CROHN DISEASE; HUMAN; ILEITIS; ILEUM; INNATE IMMUNITY; INTESTINE FLORA; LACTOBACILLUS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; STREPTOCOCCUS; TREATMENT INDICATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 37249011296     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2007.06.003     Document Type: Note

References (53)

1. Macfarlane G.T., and Cummings J.H. Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health?. Br Med J 318 (1999) 999-1003
2. Roller M., Rechkemmer G., and Watzl B. Prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune functions in rats. J Nutr 134 (2004) 153-156
3. Drakes M., Blanchard T., and Czinn S. Bacterial probiotic modulation of dendritic cells. Infect Immun 72 (2004) 3299-3309
4. Hart A.L., Lammers K., Brigidi P., Vitali B., Rizzello F., Gionchetti P., et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53 (2004) 1602-1609
5. Smits H.H., Engering A., van der Kleij D., de Jong E.C., Schipper K., et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 115 (2005) 1260-1267
6. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124 (2003) 1202-1209
7. Gionchetti P., Rizzello F., Venturi A., Brigidi P., Matteuzzi D., Bazzocchi G., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 305-309
8. Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53 (2004) 108-114
9. Kuisma J., Mentula S., Jarvinen H., Kahri A., Saxelin M., and Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 17 (2003) 509-515
10. Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., and Axon A.T.M. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354 (1999) 635-639
11. Kruis W., Fric P., Pokrotnieks J., Lukás M., Fixa B., Kascát M., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 (2004) 1617-1623
12. Ishikawa H., Akedo I., Umesaki Y., Tanaka R., Imaoka A., and Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 22 (2002) 56-63
13. Kato K., Mizuno S., Umesaki Y., Ishii Y., Sugitani M., Imaoka A., et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 20 (2004) 1133-1141
14. Tursi A., Brandimarte G., Giorgetti G.M., Forti G., Modeo M.E., and Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10 (2004) 126-131
15. Prantera C., Scribano M.L., Falasco G., Andreoli A., and Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51 (2002) 405-409
16. Marteau P., Lémann M., Seksik P., Laharie D., Colombel J.-F., Bouhnik Y., et al. Ineffectiveness of the probiotic strain Lactobacillus jonhsonii La1 in preventing recurrence after curative resection for Crohn's disease-A randomized double-blind placebo-controlled trial. Gut 55 (2006) 842-847
17. Van Gossum A., Dewit O., Geboes K., Baert F., De Vos M., Louis E., et al. A randomized placebo-controlled clinical trial of probiotics (L. jonhsonii, La1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Gastroenterology 128 (2005) A17 [abstract]
18. Campieri M., Rizzello F., Venturi A., Poggioli G., Ugolini F., Helwig U., et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalamine. Gastroenterology 118 Suppl 2 (2000) A781 [abstract]
19. Rutgeerts P., Peeters M., Hiele M., Kerremans R.P., Penninckx F.M., Aerts R., et al. A placebo controlled trial of metronidazole for recurrence prevention of Crohn's disease after resection of the terminal ileum. Gastroenterology 108 (1995) 1617-1621
20. Rutgeerts P., van Assche G., Vermeire S., D'Haens G.R., Baert F., Noman M., et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128 (2005) 856-861
21. Schultz M., Timmer A., Herfarth H.H., Sartor R.B., Vanderhoof J.A., and Rath H.C. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 4 (2004) 1-4
22. Bousvaros A., Guandalini S., Baldassano R.N., Botelho C., Evans J., Ferry G.D., et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 11 (2005) 833-839
23. Guslandi M., Mezzi G., Sorghi M., and Testoni P.A. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45 (2000) 1462-1464
24. Rolfe V.E., Fortun P.J., Hawkey C.J., and Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 4 (2006) CD004826
25. Tamboli C.P., Neut C., Desreumaux P., and Colombel J.-F. Dysbiosis in inflammatory bowel disease. Gut 53 (2004) 1-4
26. Seksik P., Rogottier-Gois L., Gramet G., Sutren M., Pochart P., Marteau P., et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 52 (2003) 237-242
27. Swidsinsky A., Ladhoff A., Pernthaler A., Swidsinsky S., Loening-Bauke V., Ortner M., et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 122 (2002) 44-54
28. Seksik P., Lepage P., Cochetière M.-F., Bourreille A., Sutren M., Galmiche J.P., et al. Search for localized dysbiosis in Crohn's disease ulcerations by temporal temperature gradient gel electrophoresis of 16S rRNA. J Clin Microbiol 43 (2005) 4654-4658
29. Swidsinsky A., Weber J., Loening-Bauke V., Hale L.P., and Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 43 (2005) 3380-3389
30. Martínez-Medina M., Aldeguer X., González-Huix F., Acero D., and García-Gil L.J. Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm Bowel Dis 12 (2006) 1136-1145
31. Bibiloni R., Mangold M., Madsen K.L., Fedorak R.N., and Tannock G.W. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol 55 (2006) 1141-1149
32. Darfeuille-Michaud A., Boudeau J., Bulois P., Neut C., Glasser A., Barnich N., et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127 (2004) 412-421
33. Kotlowski R., Bernstein C.N., Sepehri S., and Krause D.O. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 56 (2007) 669-675
34. Müller C.A., Autenrieth I.B., and Peschel A. Innate defenses of the intestinal epithelial barrier. Cell Mol Life Sci 62 (2005) 1297-1307
35. Hao W.L., and Lee Y.K. Microflora of the gastrointestinal tract: a review. Methods Mol Biol 268 (2004) 491-502
36. Wehkamp J., Schmid M., and Stange E.F. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol 23 (2007) 370-378
37. Wehkamp J., Schmid M., Fellermann K., and Stange E.F. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol 77 (2005) 460-465
38. O'Neil D.A., Porter E.M., Elewaut D., Anderson G.M., Eckmann L., Ganz T., et al. Expression and regulation of the human β-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 163 (1999) 6718-6724
39. Cunliffe R.N., Rose F.R., Keyte J., Abberley L., Chan W.C., and Mahida Y.R. Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. Gut 48 (2001) 176-185
40. Bevins C.L. Events at the host-microbial interface of the gastrointestinal tract V. Paneth cell defensins in intestinal host defense. Am J Physiol 289 (2005) G173-G176
41. Wehkamp J., Fellermann K., Herrlinger K.R., Baxmann S., Schimidt K., Schwind B., et al. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol 14 (2002) 745-752
42. Fahlgren A., Hammarström S., Danielsson A., and Hammarström M.L. β-Defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. Clin Exp Immunol 137 (2004) 379-385
43. Wehkamp J., Harder J., Weichenthal M., Mueller O., Herrlinger K.R., Fellermann K., et al. Inducible and constitutive defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 9 (2003) 215-223
44. Wehkamp J., Harder J., Weichenthal M., Schwab M., Schäffeler E., Schlee M., et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal β-defensin expression. Gut 53 (2004) 1658-1664
45. Wehkamp J., Salzman N.H., Porter E., Nuding S., Weichenthal M., Petras R.E., et al. Reduced Paneth cell β-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 102 (2005) 18129-18134
46. Ogura Y., Lala S., Xin W., Smith E., Dowds T.A., Chen F.F., et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 52 (2003) 1591-1597
47. Van Heel D.A., Ghosh S., Hunt K.A., Mathew C.G., Forbes A., Jewell D.P., et al. Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut 54 (2005) 1553-1557
48. Franchimont D., Vermeire S., El Housni H., Pierik M., Van Steen K., Gustot T., et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53 (2004) 987-992
49. Wehkamp J., Harder J., Wehkamp K., Wehkamp-von Meissner B., Schlee M., Enders C., et al. NF-κB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 72 (2004) 5750-5758
50. Furrie E., Macfarlane S., Kennedy A., Cummings J.H., Walsh S.V., O'Neil D.A., et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54 (2005) 242-249
51. Rutgeerts P., Geboes K., Peeters M., Hiele M., Penninckx F.M., Aerts R., et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 338 (1991) 771-774
52. D'Haens G.R., Geboes K., Peeters M., Baert F., Penninckx F.M., and Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114 (1998) 262-267
53. Prantera C. Probiotics for Crohn's disease: what have we learned?. Gut 55 (2006) 757-759